Deutsche Bank Comments on Intercept Pharmaceuticals (ICPT) Weakness
Tweet Send to a Friend
Deutsche Bank maintained a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT) with a price target of $500. Analyst Alethia Young ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
